Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Palmitoylation" patented technology

Palmitoylation is the covalent attachment of fatty acids, such as palmitic acid, to cysteine (S-palmitoylation) and less frequently to serine and threonine (O-palmitoylation) residues of proteins, which are typically membrane proteins. The precise function of palmitoylation depends on the particular protein being considered. Palmitoylation enhances the hydrophobicity of proteins and contributes to their membrane association. Palmitoylation also appears to play a significant role in subcellular trafficking of proteins between membrane compartments, as well as in modulating protein–protein interactions. In contrast to prenylation and myristoylation, palmitoylation is usually reversible (because the bond between palmitic acid and protein is often a thioester bond). The reverse reaction in mammalian cells is catalyzed by acyl-protein thioesterases (APTs) in the cytosol and palmitoyl protein thioesterases in lysosomes. Because palmitoylation is a dynamic, post-translational process, it is believed to be employed by the cell to alter the subcellular localization, protein–protein interactions, or binding capacities of a protein.

Application of TEAD1 palmitoylation inhibitor VT103 in preparation of PD-1 immune checkpoint antibody sensitization drug

The invention discloses application of a TEAD1 palmitoylation inhibitor VT103 in preparation of a PD-1 immune checkpoint antibody sensitization drug, and belongs to the technical field of tumor immunotherapy. It is confirmed for the first time that TEAD palmitoylation inhibition can overcome immunotherapy drug resistance of MSS tumors by regulating and controlling the state of the microsatellite, a brand new action target is provided for clinical development of immune checkpoint inhibitor sensitizing drugs, microsatellite instability is induced firstly, then immunotherapy is carried out in a combined mode, and therefore the treatment effect is improved.
Owner:YUNNAN UNIV

Application of palmitoylation inhibitor in prevention and treatment of gastric cancer

PendingCN121868279Aspeed up progressAccelerate malignant progressionAntibacterial agentsDigestive systemCD8Therapeutic effect
The invention discloses application of a palmitoylation inhibitor in prevention and treatment of gastric cancer. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis

The invention discloses an application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Palmitoylation of the alternative amino terminus of the BTK-c isoform controls subcellular distribution and signaling

The BTK-C isoform is expressed in human breast and prostate cancer cells and it plays a crucial role in epithelial cancer cell survival. BTK-C has a 34 amino acid extension to the n-terminus that facilitate it being palmitoylated on two cysteine residues. This modification localizes BTK-C closer to the cell membrane where it plays a role in improving cancer cell survival, as compared to BTK-A. BTK-C is not found to be expressed in healthy adult cells, whereas BTK-A is necessary for immune cell production. Disclosed herein are alternative kinases besides BTK having similar attributes, which present therapeutic opportunities for the treatment of cancers, especially for solid tumors.
Owner:THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK

Aniline pyridine TEAD degradation agent as well as preparation method and application thereof

The invention belongs to the technical field of new applications of medicines, and particularly relates to an aniline pyridine TEAD degradation agent, a preparation method thereof and an application of the degradation agent in preparation of antitumor drugs. According to the research, a novel aniline pyridine TEAD degradation agent with a clear structure is designed and synthesized by coupling a TEAD palmitoylation inhibitor niflumic acid serving as a lead compound with a CRBN type E3 ligase ligand through connecting chains with different lengths and different types by virtue of a computer-aided drug design means. The influence of the optimal compound (XY-3L) on cancer cell proliferation and cell functions is detected in an in-vitro cell experiment, and the curative effect of the optimal compound (XY-3L) in a melanoma lung metastasis model is explored in vivo.
Owner:THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV

Application of integrin beta3 inhibitor RGDfK in preparation of medicine for treating fatty liver disease related to metabolic dysfunction

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Application of a compound based on a 3-phenyl-1,2,4-oxadiazole-5-carboxamide skeleton in the preparation of drugs for treating tumor diseases

The present invention provides the use of a compound based on a 3-phenyl-1,2,4-oxadiazole-5-carboxamide skeleton in the preparation of a drug for treating tumor diseases, belonging to the field of biomedicine technology. The compound based on a 3-phenyl-1,2,4-oxadiazole-5-carboxamide skeleton provided by the present invention inhibits the activity of PPT2 and regulates the palmitoylation level of cofilin1, ultimately achieving a tumor-suppressing effect.
Owner:THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY

Application of compound based on 3-phenyl-1,2,4-oxadiazole-5-carboxamide scaffold in preparation of drug for treating tumor diseases

Disclosed is an application of a compound based on a 3-phenyl-1,2,4-oxadiazole-5-carboxamide scaffold in the preparation of a drug for treating tumor diseases. The compound of the 3-phenyl-1,2,4-oxadiazole-5-carboxamide scaffold regulates the level of Cofilin1 palmitoylation modification by inhibiting the activity of PPT2, and finally achieves an anticancer effect.
Owner:KONG ERYAN

Bis-substituted phenyl acrylamide / ester compound as well as preparation method and application thereof

The invention provides a bis-substituted phenyl acrylamide / ester compound as well as a preparation method and application thereof. The structural formula of the compound is shown as a formula (I) or a formula (II). The compound provided by the invention can be used as a covalent inhibitor of DHHC family proteins, and inhibits proliferation, migration and invasion of tumor cells and plays an anti-tumor role by inhibiting the activity of DHHC palmitoyltransferase and blocking the palmitoylation modification process of substrate proteins. Experimental results show that the bis-substituted phenylacrylamide / ester compound has remarkable anti-proliferative activity on various tumor cells, the inhibition effect of the compound is superior to that of a positive control drug 2-BP, and the bis-substituted phenylacrylamide / ester compound has the potential of being further developed into a new generation of efficient and low-toxicity anti-tumor drugs.
Owner:HEBEI UNIVERSITY

TEAD inhibitor

The invention discloses a TEAD inhibitor, which comprises a compound as shown in a general formula (I) or a general formula (II), and a stereoisomer or a salt thereof: the two compounds break through the limitation that the existing inhibitor only depends on a single non-covalent interaction through a hydrophobic effect, a hydrophilic effect and a multi-dimensional mechanism of covalent binding; the invention provides two brand new skeletons of carboxylic acid and acrylamide, enriches the structural types of the TEAD inhibitor, realizes more efficient and more specific inhibition of TEAD transcriptional activity through accurate design of different regions of a palmitoylated pocket, provides a candidate compound library with various structures for developing high-activity and high-selectivity antitumor drugs, and has a wide application prospect. The problems of insufficient activity, low selectivity and single structure of inhibitors in the prior art are effectively solved.
Owner:XI AN JIAOTONG UNIV

Application of palmitoylation inhibitor in induction of macrophage apoptosis

The invention discloses application of a palmitoylation inhibitor in induction of macrophage apoptosis, belongs to the technical field of biological medicines, and particularly relates to a preparation method of a pharmaceutical composition, which comprises the following steps: mixing the palmitoylation inhibitor with a medical reagent to prepare the pharmaceutical composition, the palmitoylation inhibitor is 2-BP, and the usage amount of the 2-BP is 0.0015-0.07 wt% of the medical reagent. According to the application, CPT1A expression in the pathological state macrophages is specifically up-regulated by using a palmitoylation inhibitor 2-BP, so that apoptosis of the macrophages is selectively induced, the influence on normal cells is relatively small, and a safety window of treatment is remarkably improved. The pharmaceutical composition can effectively induce apoptosis of macrophages, reduce non-specific killing of normal cells, and treat diseases related to abnormal activation or accumulation of macrophages.
Owner:ZHEJIANG CANCER HOSPITAL

Use of a u2af homology motif kinase 1 in regulating gastric cancer cells

PendingCN122357719AApoptosisSignalling pathways
This application relates to the field of biotechnology, and more particularly to the application of a U2AF homologous motif kinase 1 in gastric cancer cells. The application includes using UHMK1 as a regulator to modulate the proliferation of gastric cancer cells by regulating the zDHHC17-mediated palmitoylation-modified AKT / mTOR signaling pathway. This application is based on previous research finding that UHMK1 is highly expressed during the proliferation of gastric cancer cells. Knocking down or interfering with UHMK1 expression can clearly observe apoptosis in gastric cancer cells. Subsequent analysis of the expression levels of genes related to the UHMK1 signaling pathway, as well as changes in zDHHC17 expression levels, suggests that UHMK1 drives gastric cancer cell proliferation by regulating the zDHHC17-mediated palmitoylation-modified AKT / mTOR signaling pathway, thus filling a gap in the correlation between UHMK1 and gastric cancer.
Owner:PEOPLES HOSPITAL OF INNER MONGOLIA AUTONOMOUS REGION

Targeting beta-catenin palmitoylation small-molecule inhibitor and application thereof in treatment of colorectal cancer

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted beta-catenin palmitoylation small-molecule inhibitor and application thereof in treatment of colorectal cancer. The application of beta-cat-Oxazole in preparation of the medicine for treating the colorectal cancer is provided for the first time, the beta-cat-Oxazole can specifically target an interaction interface (residues near C466) of ZDHHC5 and beta-catenin, and other functions or normal physiological signal channels of the beta-catenin are not affected. Due to the accuracy, the miss-target risk is remarkably reduced, and a treatment window is wider. The compound can be used as a single drug in a preclinical model to significantly inhibit tumor growth; in an AOM / DSS induced colorectal cancer model, the tumor load is reduced by about 50%. In addition, the invention discloses a core mechanism of a targeted ZDHHC5-beta-catenin interaction interface, and a new structural basis is provided for subsequent drug target design.
Owner:SUN YAT SEN UNIVERSITY SHENZHEN +1

Prebiotic polypeptide compound preparation for improving intestinal health and preparation method thereof

The invention discloses a prebiotic polypeptide compound preparation for improving intestinal health and a preparation method of the prebiotic polypeptide compound preparation, and belongs to the technical field of polypeptide preparations. The prebiotic polypeptide compound preparation is prepared from the following raw materials: N-terminal palmitoylated polypeptide-FOS, compound bacteria liquid and DTSSP. The polypeptide and the probiotics are compounded to form nano-micelles, the nano-micelles are combined with the prebiotics, the activity and stability of the prebiotics and the probiotics are optimized, and the compound preparation of the N-terminal palmitoylated polypeptide and the prebiotics (FOS) can promote growth and reproduction of the probiotics in intestinal tracts; the polypeptide nano-micelles and the probiotics are compounded, so that the stability and tolerance of the probiotics are enhanced, and the survival ability of the probiotics at the far end of the intestinal tract is also improved.
Owner:佛山市生物医学工程学会

Polypeptide targeting palmitoylation modification of aplnr protein and its application in treatment of cancer pain

ActiveCN115920057Brelieve toleranceReduce spontaneous painOrganic active ingredientsPeptide/protein ingredientsMorphine toleranceCancer pain
The application discloses a polypeptide targeting palmitoylation modification of APLNR protein and application thereof in cancer pain treatment, in particular, application of APLNR protein and a palmitoylation modification site of the APLNR protein in relieving morphine tolerance in treatment of cancer pain. It is found by the application that the palmitoylation modification of APLNR is one of important response factors of neuropathic cancer pain, and a polypeptide targeting palmitoylation modification of APLNR protein is developed by taking the APLNR protein as a target, and the polypeptide is combined with morphine to treat cancer pain, so that the cancer pain can be effectively reduced, and the occurrence of morphine tolerance can be relieved, thereby providing a new strategy for clinical treatment of cancer pain and relief of morphine tolerance.
Owner:HEFEI INSTITUTE OF PHYSICAL SCIENCE CHINESE ACADEMY OF SCIENCES

A porcine epidemic diarrhea virus with low replication ability and its construction method and application

The present invention discloses a porcine epidemic diarrhea virus with low replication ability, a construction method and an application thereof, and relates to the field of biomedicine technology. The construction method includes the steps of mutating the amino acids 1347 and 1348 of the S protein of porcine epidemic diarrhea virus AH2012 / 12 into serine to construct a recombinant virus; the recombinant virus is a porcine epidemic diarrhea virus with low replication ability. The present invention evaluates the immunogenicity of the recombinant virus, and the results show that the recombinant virus can induce the production of high levels of PEDV S protein IgG antibodies and neutralizing antibodies, and the antibody level produced exceeds that of its parent strain AH2012 / 12 28 days after immunization. These results indicate that the two palmitoylation modification sites of the recombinant virus can increase the antibody level and are important targets for reducing the viral replication ability. The present invention lays an important foundation for the research and development of new attenuated vaccines for porcine epidemic diarrhea virus.
Owner:JIANGSU ACAD OF AGRI SCI

Hydrophobic modifications to proteins

The disclosure provides, in various embodiments, polynucleotides encoding a fusion protein, wherein the polynucleotides comprise: (a) a protein coding sequence encoding a non-Hedgehog therapeutic protein, and (b) at least one of the following: (i) a sequence encoding a polypeptide sufficient for palmitoylation by a Hedgehog acyltransferase, wherein the polypeptide is N-terminal to the non-Hedgehog therapeutic protein, (ii) a sequence encoding a Hedgehog auto-processing domain having sterol modification activity, wherein the domain is C-terminal to the non-Hedgehog therapeutic protein, and (iii) a sequence encoding a polypeptide sufficient for palmitoylation by a membrane-bound O-acyltransferase enzyme. The disclosure also provides, in various embodiments, vectors, cells, and kits comprising the polynucleotides, and methods of using the polynucleotides, vectors, cells, and / or kits.
Owner:WHITEHEAD INST FOR BIOMEDICAL RES

Use of palmitoylation inhibitors in inducing macrophage apoptosis

The application discloses application of a palmitoylation inhibitor in inducing macrophage apoptosis, belongs to the technical field of biological medicine, and particularly relates to a preparation method of a pharmaceutical composition, which comprises the following steps: mixing the palmitoylation inhibitor with a medical reagent to prepare the pharmaceutical composition; the palmitoylation inhibitor is 2-BP, and the use amount of the 2-BP is 0.0015-0.07 wt% of the medical reagent. The application utilizes the 2-BP to specifically up-regulate the expression of CPT1A in the macrophages in a pathological state, thereby selectively inducing the apoptosis of the macrophages, has a smaller influence on normal cells, and significantly improves a safety window of treatment. The pharmaceutical composition can effectively induce the apoptosis of the macrophages, reduce non-specific killing on normal cells, and treat diseases related to abnormal activation or accumulation of the macrophages.
Owner:ZHEJIANG CANCER HOSPITAL

Compositions and methods for Anti-inflammatory peptides

PCT designated stageWO2026096636A1DepsipeptidesMacromolecular non-active ingredientsCoiled coilAmino acid
Compositions of anti-inflammatory peptides and methods of use thereof are provided. The peptides include N-terminal, palmitoylated peptides covering / derived from a coiled-coil region of CRACR2A. Methods include reducing inflammation and / or inhibiting a STIM1-CRACR2A interaction in a subject in need thereof by administering a composition of the present disclosure. Exemplary compositions include palmitoylated peptides having between about 10 and 20 amino acids.
Owner:WASHINGTON UNIV IN SAINT LOUIS

Cervical cancer influence mechanism research method based on ICAT regulated ferroptosis

The invention discloses a cervical cancer influence mechanism research method based on ICAT regulated ferroptosis, and relates to the technical field of molecular biology. Comprising the following steps: evaluating the ferroptosis effect of ICAT in cervical cancer; the ICAT is verified to promote the malignant progression of cervical cancer by inhibiting ferroptosis; the molecular mechanism of ICAT for inhibiting cervical cancer ferroptosis is clarified; and screening an anti-cervical cancer candidate compound. According to the invention, the action downstream target of ICAT is accurately positioned as GPX4 through proteomics and immunoprecipitation-mass spectrometry, and the specific mechanism of stabilizing GPX4 protein by influencing ZDHHC5-mediated palmitoylation is clarified, so that the target is very clear; a targeted drug screening strategy is designed for screening small molecule compounds, antibodies or nucleic acid drugs capable of targeting ICAT or destroying GPX4 palmitoylation, and a clear target spot and a feasible screening path are provided for developing novel anti-cervical cancer drugs.
Owner:CHONGQING MEDICAL UNIVERSITY

Methods and compositions of treating cancer by modulating palmitoylation of flotillin-1

Cancer metastasis is the leading cause of cancer related death and involves the spreading of the tumor to distant sites throughout the body. However, there are limited therapies which can effectively target this deadly process. One protein which contributes to cancer metastasis is termed flotillin-1. Its expression is associated with metastasis in several solid tumors. It is known that the addition of a fatty acid can alter this protein's biology and stabilize it (“palmitoylation”). It is herein shown that altering this process can lead to a decrease in the stability of the protein. Thus, targeting the addition of this fatty acid can lead to its degradation and be a way to successfully target this metastasis-inducing protein therapeutically.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Colorectal cancer multi-target prognosis risk assessment model construction method based on palmitoylation-related lncRNA

The invention discloses a colorectal cancer multi-target prognosis risk assessment model construction method based on palmitoylation related lncRNA, and relates to the technical field of colorectal cancer prognosis model construction. The method comprises the following steps: step 1, data acquisition; step 2, identifying lncRNA (long non-coding ribonucleic acid) related to S-palmitoylation; step 3, determining a key lncRNA (long non-coding RNA) for constructing a prognosis model; 4, establishing a risk scoring model; and 5, testing the prognosis model. Based on a TCGA database, palmitoylation related genes and CRC transcriptome data are integrated, lncRNA significantly related to the palmitoylation related genes and the CRC transcriptome data is screened through co-expression analysis, and a multi-target prognosis risk assessment model based on the palmitoylation related lncRNA is constructed. And further model testing and mechanism exploration, immune infiltration and mutation load evaluation, drug sensitivity prediction and the like are carried out, so that a more accurate prognosis evaluation tool is expected to be provided for CRC patients, the development of mechanism-driven individualized treatment strategies is promoted, and the method has important significance in improving treatment of the patients and increasing the survival rate.
Owner:NANCHANG UNIV

Application of isoborneol and derivatives thereof in preparation of osteoarthritis medicines and medicines

The invention discloses application of isoborneol and derivatives thereof in preparation of osteoarthritis medicines and the medicines, and relates to the technical field of biological medicines. The invention relates to application of isoborneol and derivatives thereof in preparation of osteoarthritis drugs, in particular to application of isoborneol or pharmaceutically acceptable salts, esters, solvates or prodrugs thereof in preparation of osteoarthritis prevention and / or treatment drugs. The invention discloses that isoborneol can specifically enhance METTL3 S-palmitoylation, so that the isoborneol can be applied to preparation of medicines for preventing and / or treating osteoarthritis.
Owner:GUANGDONG VOCATIONAL & TECHNICAL COLLEGE

Use of palmitoyltransferase zdhhc21 in preparation of drugs for treating breast cancer

This invention belongs to the field of biomedicine and discloses the application of palmitoyltransferase ZDHHC21 in the preparation of drugs for treating breast cancer. This invention demonstrates that ZDHHC21 knockdown upregulates RIPK1 expression, which is related to signal feedback induced by CD82 palmitoylation deficiency. Depalmitoylated CD82 competitively binds to RIPK1 inhibitory molecules, thereby releasing the regulation of RIPK1, promoting the interaction and phosphorylation activation of RIPK1 and RIPK3, and subsequently upregulating MLKL expression and inducing its activation. Downstream activation of Caspase-3 ultimately initiates necroptosis. A specific regulatory axis of "ZDHHC21–CD82–pan-apoptosis" is established. This provides a potential novel therapeutic target for triple-negative breast cancer and offers a theoretical and experimental basis for therapeutic strategies targeting tumor cell death. Further research can explore the role of this regulatory axis in vivo, providing support for clinical translation.
Owner:THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV

Application of palmitoylation modification inhibitor in preparation of medicine for treating or relieving allergic airway inflammation

The invention relates to application of a palmitoylation modification inhibitor in preparation of a medicine for treating or relieving allergic airway inflammation. The palmitoylation modified inhibitor is applied to the field of treatment of allergic airway inflammatory diseases for the first time. Experimental results show that the inhibitor can significantly inhibit activation of a JAK1 / STAT6 signal channel in vitro and effectively inhibit secretion of Th2 type inflammatory factors such as IL-4 and IL-13 by eosinophilic granulocytes; in animal model research, the palmitoylation modification inhibitor can obviously relieve allergic airway inflammatory reaction of mice, and the allergic airway inflammatory reaction is specifically shown as reduction of the number of eosinophils in bronchoalveolar lavage fluid (BALF), reduction of expression and secretion levels of BALF and lung tissue Th2 type inflammatory factors and obvious relieving of lung inflammation pathological degree. The invention provides a theoretical basis and a potential target for clinically developing a novel therapeutic drug for allergic airway inflammatory diseases in the future.
Owner:ZHEJIANG UNIV

Nucleic acid molecules encoding modified retroviral gag proteins and uses thereof

PendingCN122278889AIncrease productionhigh titerInitiating MethionineRetrovirus
This invention discloses a nucleic acid molecule encoding a modified retroviral Gag protein and its applications. The Gag protein contains an engineered acylated tag sequence at its N-terminus, comprising: a glycine residue at the second position after the initiating methionine for myristylation modification; and / or a cysteine ​​residue in the N-terminal region for palmitoylation modification. The tag sequence is selected from SEQ ID NO:1, 3-9, or derivative amino acid sequences having at least 80% identity and retaining function. Preferably, the modification involves replacing the first 9 amino acids at the N-terminus of the wild-type HIV-1 Gag protein with the aforementioned tag to enhance membrane anchoring and improve viral packaging efficiency. This invention also provides packaging plasmids containing this molecule, host cells, packaging systems, and preparation methods. This invention can significantly improve viral yield and titer, and is particularly suitable for overcoming the efficiency bottleneck in packaging large-load lentiviruses of 7-10 kb.
Owner:TSINGHUA UNIVERSITY

Pharmaceutical composition for overcoming drug resistance of lenvatinib and application

PendingCN122031694APromote cytoplasmic translocationavoid sensitivityBioreactor/fermenter combinationsBiological substance pretreatmentsLenvatinibHepatocellular carcinoma
The invention relates to the technical field of biology, in particular to a pharmaceutical composition capable of overcoming drug resistance of lenvatinib and application of the pharmaceutical composition. The pharmaceutical composition comprises an active ingredient targeting a KDM4A-AS1 / ZDHHC3 / WNK1 regulation axis; the active component is at least one of a KDM4A-AS1 targeting inhibitor, a ZDHHC3 targeting inhibitor or a palmitoylation inhibitor of WNK1 at a Cys411 site, and a pharmaceutically acceptable carrier of the active component. The KDM4A-AS1 / ZDHHC3 / WNK1 axis is used for driving the drug resistance of hepatocellular carcinoma (HCC) to lenvatinib by inhibiting pyroptosis. Therefore, each constituent part of the shaft represents a promising treatment target, and a feasible strategy can be provided for restoring the sensitivity of a patient with advanced hepatocellular carcinoma to lenvatinib by inhibiting each treatment target; the compound has a wide prospect in preparation of drugs for treating hepatocellular carcinoma or overcoming drug resistance of hepatocellular carcinoma to lenvatinib.
Owner:GUIGANG PEOPLES HOSPITAL